Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
Status:
Withdrawn
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: The Epstein-Barr virus can cause cancer and lymphoproliferative disorders.
Valganciclovir is an antiviral drug that acts against the Epstein-Barr virus. Phenylbutyrate
may make cells infected with Epstein-Barr virus more sensitive to valganciclovir. Giving
phenylbutyrate together with valganciclovir may block the growth of Epstein-Barr
virus-infected cells and kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving phenylbutyrate together with
valganciclovir works in treating patients with relapsed or refractory Epstein-Barr
virus-positive cancer.